# EDGAR Filing Document

**Accession Number:** 0001613103
**File Stem:** 0001628280-26-027272
**Filing Date:** 2026-4
**Character Count:** 11978
**Document Hash:** 51ac8abe78a002921e06ca7ad4f352e1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-027272.hdr.sgml**: 20260427

**ACCESSION NUMBER**: 0001628280-26-027272

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260424

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260427

**DATE AS OF CHANGE**: 20260424

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Medtronic plc
- **CENTRAL INDEX KEY:** 0001613103
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **FISCAL YEAR END:** 0424

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36820
- **FILM NUMBER:** 26895967

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** BUILDING TWO PARKMORE BUSINESS PARK WEST
- **CITY:** GALWAY
- **PROVINCE COUNTRY:** L2
- **ZIP:** H91 4K49
- **BUSINESS PHONE:** 01135314381700

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** BUILDING TWO PARKMORE BUSINESS PARK WEST
- **CITY:** GALWAY
- **PROVINCE COUNTRY:** L2
- **ZIP:** H91 4K49

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Medtronic Ltd
- **DATE OF NAME CHANGE:** 20150112

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Medtronic Holdings Ltd
- **DATE OF NAME CHANGE:** 20140711

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Kalani I Ltd
- **DATE OF NAME CHANGE:** 20140709

?xml version='1.0' encoding='ASCII'? mdt-20260424

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

_____________________________

**FORM 8-K** 

_____________________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**

**the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **April 24, 2026** 

_____________________________

**Medtronic plc**

**(Exact name of Registrant as Specified in its Charter)**

_____________________________

---

| | | |
|:---|:---|:---|
| **Ireland** | **1-36820** | **98-1183488** |
| **(State or other jurisdiction**<br>**of incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

**Building Two**

**Parkmore Business Park West**

**Galway, Ireland** 

(Address of principal executive offices) (Zip Code)

**+353 1 438-1700** 

(Registrant's telephone number, including area code)

---

| |
|:---|
| **Not Applicable** |
| Former name or former address, if changed since last report |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

------

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| **Ordinary shares, par value $0.0001 per share** | **MDT** | **New York Stock Exchange** |
| **1.125% Senior Notes due 2027** | **MDT/27** | **New York Stock Exchange** |
| **0.375% Senior Notes due 2028** | **MDT/28** | **New York Stock Exchange** |
| **3.000% Senior Notes due 2028** | **MDT/28A** | **New York Stock Exchange** |
| **3.650% Senior Notes due 2029** | **MDT/29** | **New York Stock Exchange** |
| **2.950% Senior Notes due 2030** | **MDT/30** | **New York Stock Exchange** |
| **1.625% Senior Notes due 2031** | **MDT/31** | **New York Stock Exchange** |
| **1.000% Senior Notes due 2031** | **MDT/31A** | **New York Stock Exchange** |
| **3.125% Senior Notes due 2031** | **MDT/31B** | **New York Stock Exchange** |
| **0.750% Senior Notes due 2032** | **MDT/32** | **New York Stock Exchange** |
| **3.375% Senior Notes due 2034** | **MDT/34** | **New York Stock Exchange** |
| **3.875% Senior Notes due 2036** | **MDT/36** | **New York Stock Exchange** |
| **2.250% Senior Notes due 2039** | **MDT/39A** | **New York Stock Exchange** |
| **1.500% Senior Notes due 2039** | **MDT/39B** | **New York Stock Exchange** |
| **1.375% Senior Notes due 2040** | **MDT/40A** | **New York Stock Exchange** |
| **4.150% Senior Notes due 2043** | **MDT/43A** | **New York Stock Exchange** |
| **4.200% Senior Notes due 2045** | **MDT/45** | **New York Stock Exchange** |
| **1.750% Senior Notes due 2049** | **MDT/49** | **New York Stock Exchange** |
| **1.625% Senior Notes due 2050** | **MDT/50** | **New York Stock Exchange** |
| **4.150% Senior Notes due 2053** | **MDT/53** | **New York Stock Exchange** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 7.01.** | **Regulation FD Disclosure** |

---

On April 24, 2026, Medtronic plc ("Medtronic" or the "Company") announced that an unauthorized third party had accessed data in certain of the Company's information technology ("IT") systems. Upon identifying the unauthorized access, the Company promptly took steps to contain the incident, activated its incident response protocols, and engaged leading external cybersecurity experts to support its investigation and remediation efforts.

Based on its investigation to date, Medtronic has not identified any impact to its products, patient safety, connections to customers, manufacturing and distribution operations, financial reporting systems, or ability to meet patient needs. In addition, the Company does not currently expect the incident to have a material impact on its business or financial results.

Medtronic issued a statement on its website on April 24, 2026 regarding this matter. A copy of the statement is furnished as Exhibit 99.1 to this report.

The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth in such a filing.

**Forward-Looking Statements Disclaimer**

This filing contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including statements regarding the Company's current understanding regarding the extent of the cybersecurity incident and the results or findings of the Company's investigation thereof; the Company's containment of the incident; the lack of disruption to our business or operations; and the potential impact on the Company's financial condition and results of operations. Factors that could cause actual results to differ materially from those indicated in the forward-looking statements include, but are not limited to the results of the Company's analysis of the scope and details of the cybersecurity incident; the unauthorized release of any of the Company's data, including third party data held by the Company, or the use of any such data for any fraudulent purposes; potential adverse impact of the incident on the Company's results of operations, including revenue, operating income and cash flows from operations, and on its financial condition; diversion of management's attention from operations of the Company to addressing the cybersecurity incident; potential litigation related to the cybersecurity incident; potential adverse effects on relationships with customers, suppliers, patients and other third parties as a result of the cybersecurity incident; reputational risk related to the cybersecurity incident; and regulatory scrutiny of the cybersecurity incident, and as further described in the Company's periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this filing, including to reflect future events or circumstances.

---

| | |
|:---|:---|
| **Item 9.01.** | **Exhibits.** |

---

(d) List of Exhibits

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| [99.1](exhibit991-statementdateda.htm) | [Statement dated April 24, 2026, issued by Medtronic plc.](exhibit991-statementdateda.htm) |
| 104 | Cover Page Interactive Data File (embedded with the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | | Medtronic plc |
| Date: April 24, 2026 | By | /s/ Michelle Quinn |
| | | Michelle Quinn |
| | | Executive Vice President, General Counsel |

---

## Exhibit 99.1

**Exhibit 99.1**

![image_0.jpg](image_0.jpg)

NEWS RELEASE

FOR IMMEDIATE RELEASE

Medtronic statement on unauthorized system access

April 24, 2026

Medtronic has determined that an unauthorized party accessed data in certain Medtronic corporate IT systems.

We have not identified any impact to our products, patient safety, connections to our customers, our manufacturing and distribution operations, our financial reporting systems or our ability to meet patient needs.

The networks that support our corporate IT systems, our products and our manufacturing and distribution operations are separate. Hospital customer networks remain separate from Medtronic IT networks and are secured and managed by customers' IT teams.

**What We're Doing**

Upon identifying this unauthorized access, we immediately took steps to contain the incident, activated our incident response protocols and engaged leading cybersecurity experts to support our investigation and remediation actions.

We are working to identify any personal information that may have been accessed and will provide notifications and support services as needed. We will continue to provide updates to any impacted individuals as we learn more.

**Our Commitment to our Patients, Customers and Employees**

Protecting patients and the trust placed in Medtronic is our highest priority. The privacy and security of all data with which we are entrusted is a vital part of that. As we resolve any impact of this unauthorized access to data in our systems, we are simultaneously identifying additional ways to further optimize our system security. We currently do not expect a material impact on our business or financial results.

<br>